Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial.

Abstract

REASONS FOR PERFORMING STUDY Bisphosphonates, such as tiludronate, are used to normalise bone metabolism via inhibition of bone resorption. Areas of increased bone resorption and formation are typical lesions in a diseased navicular bone. OBJECTIVES To determine if bone remodelling changes occurring in navicular disease may be corrected with therapies… (More)

Topics

Cite this paper

@article{Denoix2003TiludronateAA, title={Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial.}, author={J. - M. Denoix and Dominique Thibaud and Brett E Riccio}, journal={Equine veterinary journal}, year={2003}, volume={35 4}, pages={407-13} }